In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Feature tracking by cardiovascular magnetic resonance: left ventricular dysfunction predicts outcome in heart failure with preserved ejection fraction

Session Poster session 1

Speaker Andreas Kammerlander

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance
  • Session type : Poster Session
  • FP Number : P139

Authors : A Kammerlander (Vienna,AT), B Karner (Vienna,AT), A Keil (Vienna,AT), M Seitlhuber (Vienna,AT), C Dona (Vienna,AT), C Nitsche (Vienna,AT), F Duca (Vienna,AT), D Beitzke (Vienna,AT), C Binder (Vienna,AT), M Koschutnik (Vienna,AT), S Aschauer (Vienna,AT), C Loewe (Vienna,AT), C Hengstenberg (Vienna,AT), D Bonderman (Vienna,AT), J Mascherbauer (Vienna,AT)

Authors:
A Kammerlander1 , B Karner1 , A Keil1 , M Seitlhuber1 , C Dona1 , C Nitsche1 , F Duca1 , D Beitzke2 , C Binder1 , M Koschutnik1 , S Aschauer1 , C Loewe2 , C Hengstenberg1 , D Bonderman1 , J Mascherbauer1 , 1Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology - Vienna - Austria , 2Medical University of Vienna, Department of Radiology - Vienna - Austria ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii84

Objectives. To investigate the association between global longitudinal strain (GLS) using feature tracking (FT) cardiovascular magnetic resonance imaging (CMR) and prognosis in patients with heart failure and preserved ejection fraction (HFpEF).

Background. Echocardiography-based studies have demonstrated that in HFpEF left ventricular (LV) strain analyses can detect impaired systolic function despite preserved ejection fraction and might also predict outcome. CMR also allows strain analysis using FT and is furthermore the gold standard for assessment of ventricular volumes and ejection fractions. In addition, T1-mapping allows non-invasive tissue characterization. However, the prognostic relevance of FT-CMR is unknown. In addition right ventricular (RV) FT-CMR is poorly investigated. 

Methods. Consecutive patients with confirmed diagnosis of HFpEF underwent CMR on a 1.5T scanner. We used dedicated software (cvi42, Circle Cardiovascular Imaging Inc.) for assessment of global longitudinal left ventricular strain (LV-GLS) in a 3D and global longitudinal RV strain (RV-GLS) in a 2D model using feature tracking (FT). In addition, we performed uni- and multivariable Cox regression using a combined endpoint of heart failure hospitalizations, and cardiovascular death to determine the prognostic relevance of FT-CMR.

Results. We included a total of 115 HFpEF patients (70.4±8.6 years old, 70.2% female). Median LV-GLS by FT-CMR was -8% [IQR: -10% to 5%] and median RV-GLS was -11.9% [IQR: -16.57% to -12.23%]. LV and RV GLS values were significantly correlated with LV and RV ejection fractions (r=-0.463, p<0.001 for LV, and r=-0.306, p=0.001 and RV, respectively). In 58.8% of patients an event was recorded during a follow-up of 42.0±31.4 months. Patients with an LV-GLS worse than the median (-8%) showed a significantly reduced event-free survival rate (log-rank, p=0.023).In a multivariable Cox-regression model correcting for the strongest clinical variables, including age (HR 1.018 [0.985-1.052], p=0.290), GFR (HR 0.987 [0.975-1.000], p=0.055), diabetes (HR 1.696 [1.028-2.799], p=0.039), and 6-min-walking distance (HR 0.997 [0.995-0.999)], p=0.014), LV-GLS remained significantly associated with outcome (HR 1.093 [1.039-1.150], p=0.001) while RV-GLS had no effect on outcome (p>0.05).

Conclusions. In patients with HFpEF, LV-GLS but not RV-GLS by FT-CMR is significantly associated with cardiovascular events.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are